New COVID-19 vaccination recommendations in Spain: Optimizing for next seasons
Enfermedades infecciosas y microbiologia clinica (English ed ),
Год журнала:
2025,
Номер
43(1), С. 36 - 46
Опубликована: Янв. 1, 2025
Despite
high
initial
vaccination
rates,
Spain's
current
COVID-19
coverage
in
recommended
groups
does
not
meet
WHO
targets.
For
the
upcoming
season,
challenges
include
revising
age,
updating
risk
groups,
and
unifying
criteria
with
flu
vaccine
co-administration.
European
Commission's
advance
purchase
agreements
limit
access
to
certain
vaccines,
need
for
vaccines
effective
against
variants
adds
administrative
complexities.
recommendations
should
adapt
these
specific
circumstances.
Using
predominant
appropriate
response
duration
is
crucial
protect
at-risk
populations.
Enhancing
training
health
education
campaigns
professionals
general
public,
alongside
utilizing
tools
simplify
recommendations,
can
promote
higher
rates
Spain.
Addressing
essential
ensure
adequate
protection
improve
coverage,
ultimately
achieving
better
public
outcomes
face
of
evolving
threats.
Язык: Английский
Cost-Effectiveness of Introducing Nuvaxovid to COVID-19 Vaccination in the United Kingdom: A Dynamic Transmission Model
Vaccines,
Год журнала:
2025,
Номер
13(2), С. 187 - 187
Опубликована: Фев. 14, 2025
Background/Objectives:
Vaccination
against
SARS-CoV-2
remains
a
key
measure
to
control
COVID-19.
Nuvaxovid,
recombinant
Matrix-M-adjuvanted
protein-based
vaccine,
showed
similar
efficacy
mRNA
vaccines
in
clinical
trials
and
real-world
studies,
with
lower
rates
of
reactogenicity.
Methods:
To
support
decision
making
on
UK
vaccine
selection,
population-based
compartmental
dynamic
transmission
model
cost-utility
component
was
developed
evaluate
the
cost-effectiveness
Nuvaxovid
compared
from
National
Health
Service
perspective.
The
calibrated
official
epidemiology
statistics
for
mortality,
incidence,
hospitalisation.
Scenario
sensitivity
analyses
were
conducted.
Results:
In
probabilistic
base
case,
Nuvaxovid-only
strategy
provided
total
incremental
cost
savings
GBP
1,338,323
1558
additional
quality-adjusted
life
years
(QALYs)
an
mRNA-only
vaccination
strategy.
Cost
driven
by
reduced
cold
chain-related
operational
costs
wastage,
while
QALY
gains
potential
differences
tolerability.
Probabilistic
analysis
indicated
approximately
70%
probability
versus
across
most
thresholds
(up
300,000/QALY
gained).
Conclusions:
remained
dominant
over
scenario
assessing
waning,
market
shares,
vaccinated
population.
Язык: Английский
What Is Next for COVID-19 Vaccination?
Seminars in Respiratory and Critical Care Medicine,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 31, 2025
Abstract
Whenever
a
new
COVID-19
vaccination
season
starts,
we
must
face
challenges,
including
which
vaccines
to
use,
the
update
of
high-risk
groups
be
vaccinated,
and
especially
type
amount
information
communicated
people
in
order
promote
vaccination.
recommendations
should
fit
these
specific
conditions.
The
use
effective
against
predominant
SARS-CoV-2
virus
variants
extent
immune
response
(waning
immunity)
are
key
aspects
try
protect
better
populations.
Updated
currently
swiftly
available.
However,
number
vaccinated
with
any
additional
booster
dose
is
declining.
Improved
health
training
for
care
professionals,
together
tools
make
simpler
recommendations,
can
encourage
higher
rates.
Addressing
challenges
essential
improve
coverage
ensure
adequate
protection
evolving
threats.
has
become
constant
presence
our
society.
changes
but
neither
endemic
nor
seasonal
so
far.
Omicron
variant
prevailed
nearly
2
years
now
several
its
subvariants
like
JN.1,
KP.2,
or
XEC
dominant
ones.
In
this
moving
situation,
main
message
same:
safe
effective.
role
current
efforts
mitigate
severity
disease
reduce
risk
complications
death,
instead
preventing
most
infections.
New
at
different
stages
clinical
research.
Язык: Английский
New COVID-19 vaccination recommendations in Spain: Optimizing for next seasons
Enfermedades Infecciosas y Microbiología Clínica,
Год журнала:
2024,
Номер
43(1), С. 36 - 46
Опубликована: Окт. 8, 2024
Despite
high
initial
vaccination
rates,
Spain's
current
COVID-19
coverage
in
recommended
groups
does
not
meet
WHO
targets.
For
the
upcoming
season,
challenges
include
revising
age,
updating
risk
groups,
and
unifying
criteria
with
flu
vaccine
co-administration.
European
Commission's
advance
purchase
agreements
limit
access
to
certain
vaccines,
need
for
vaccines
effective
against
variants
adds
administrative
complexities.
recommendations
should
adapt
these
specific
circumstances.
Using
predominant
appropriate
response
duration
is
crucial
protect
at-risk
populations.
Enhancing
training
health
education
campaigns
professionals
general
public,
alongside
utilizing
tools
simplify
recommendations,
can
promote
higher
rates
Spain.
Addressing
essential
ensure
adequate
protection
improve
coverage,
ultimately
achieving
better
public
outcomes
face
of
evolving
threats.
Язык: Английский